Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Actelion Ltd
Bosentan in pulmonary arterial hypertension study useful for Eisenmenger
August 10th, 2005
Actelion Ltd (ATLN) announced that in the BREATHE-5 study evaluating the use of Tracleer (bosentan) in pulmonary arterial hypertension (PAH) related to Eisenmenger syndrome, patients significantly increased their exercise capacity and decreased pulmonary vascular resistance (PVR) under treatment. Patients suffering from Eisenmenger syndrome develop a severe form of PAH as a complication of their congenital heart defect. This syndrome cannot be treated by any conventional means, including surgery. BREATHE-5 is a multi-center, randomized, double-blind, placebo-controlled study to show benefit in these sick patients. The standard regime of Tracleer was used and patients...
Source: Biotech Week (2005-08-10)
|
